COVID-19
Convalescent Plasma
Training Slides
Training Outline

- Convalescent Plasma (CP) COVID-19
- RECOVERY Trial overview
- Consent and Randomisation to Recovery trial CP arm
- Convalescent Plasma Dose
- Samples required before administering CP
- Issuing CP
- Transfer and administration of CP
- Assessment of safety of CP
Convalescent Plasma COVID-19

Convalescent plasma COVID-19 FFP (CP) is plasma donated from people who have recovered from COVID-19 and contains antibodies that may help treat COVID-19.

This is a new product and must ONLY be used for clinical trials.
RECOVERY Trial:

- A national clinical trial aiming to identify and compare several different treatments that may be beneficial for adults and children hospitalised with confirmed Covid-19.
  - Lopinavir-Ritonavir (commonly used to treat HIV); corticosteroids – stopped as enough people enrolled in this arm and proved to be effective; hydroxychloroquine - recruitment stopped as shown to be ineffective; azithromycin (commonly-used antibiotic). For patients, whose condition is more severe, tocilizumab (a treatment for rheumatoid arthritis) is also an option (second randomisation).
- Convalescent Plasma (CP) has recently been added to the trial experimental treatments.
- CP is administered as part of the trial only.
- Patients will be randomised (Randomisation A) to the trial treatments, then concurrently randomised (Randomisation B) to CP vs No CP on a 1:1 basis.
Consent and Randomisation

6. **OPTIONAL: Convalescent plasma:** I am aware that I may be offered convalescent plasma as one of the treatments I may receive. I have indicated my agreement (or not) to receive this by initialing the appropriate box.

NHSBT is currently designing a CP leaflet and we will share this with you once approved.
Randomisation

• Randomisation is performed via RECOVERY trial website

• Patient allocated with unique trial ID (7 digits)

• 1st Group and Screen sample should be sent as soon as the patient has given consent.

• If a patient is randomised to receive CP the research team must:
  – notify the transfusion laboratory ASAP
  – provide transfusion laboratory with unique patient trial ID number (can be added in the CP request form)
  – Send the second G & S sample if required
Convalescent Plasma – Adult Dose

**Adult patients**

- One unit of 275 ml ± 75ml of ABO compatible CP on study days 1 and 2.
- ABO identical plasma is preferred if available.
- Minimum of 12 hour interval between 1st and 2nd units.
- The second unit of CP should be from a different donor (where possible).
- Two units administered to maximise potential for patients to receive high antibody levels
Convalescent Plasma – Paediatric and Neonate Dose

- 5ml/kg of ABO compatible CP intravenous up to standard adult dose of 275 mls per day on study days 1 & 2.
  - Prescription must specify volume of CP to be given according to child’s weight.
- Minimum of 12 hour interval between 1st and 2nd units.
- The second unit should be from a different donor where possible
- CP for neonates and infants up to one year of age needs to be ordered on a named patient basis to ensure the unit meets neonatal requirements – this will be in paediatric packs – 4 from one adult unit.
  - All the usual testing as for paediatric FFP
  - NB please allow extra time for delivery; they will be manufactured and stored at NHSBT Colindale Centre.
- CP for children above one year of age, you will need to use an adult unit – administer the prescribed volume according to child’s weight and discard the remainder.
Samples required for the transfusion laboratory

- Basic training for Principal Investigators regarding CP is included on the RECOVERY website [www.recoverytrial.net](http://www.recoverytrial.net)

- They have been told:
  - in order for the transfusion laboratory to issue the convalescent plasma (CP) they need to have 2 Group and Screen (G & S) samples on their system. These must have been taken at separate occasions.
  - Collect the 1st Group and Screen sample as soon as the patient has given consent
  - The transfusion lab may have 1 on the system already, if another is required take it after randomisation.
  - These samples are important to avoid transfusion errors
Issuing CP

- Each unit must be requested and issued as separate events.
- 1 unit of ABO compatible CP defrosted as per normal transfusion laboratory procedures (ABO matched/identical if possible; use standard grouping practice).
- Issue CP via LIMS or other standard systems.
- Laboratory staff must record the patient's trial number in the Convalescent Plasma Log: download via LIMS system or use the electronic/paper version we sent you. Provide to CTU@nhsbt.nhs.uk weekly.

<table>
<thead>
<tr>
<th>Trial and Patient Trial ID</th>
<th>Unit</th>
<th>Donation ID of Issued Convalescent Plasma</th>
<th>Date and Time Issued</th>
<th>Issuer Name</th>
<th>Confirmed Fate of Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>REMAP-CAP</td>
<td></td>
<td>G----------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RECOVERY</td>
<td>Unit 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unit 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relevant Trial ID</td>
<td></td>
<td>G----------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Hospital Stock

• Prior to the green light to start recruiting to RECOVERY-CP
  **We will authorise the OBOS team** to issue your site:
  • ~6 Units of A
  • ~2 Units of O

• Units of AB and B and CP for neonates and infants up to 1 year of age will need to be ordered on a case by case basis

• CP has its own unique product code (**barcodes on next slide**)

• This stock must be stored in the transfusion laboratory **separately from other blood products** at -25°C

• Subsequent stocks can be ordered from the OBOS system: **OBOS@nhsbt.nhs.uk**

• **Convalescent plasma must be issued for TRIAL USE ONLY**

• Please consider logistics and weekend cover
<table>
<thead>
<tr>
<th>Component description</th>
<th>NHSBT Pulse Code</th>
<th>Start Code</th>
<th>Barcode No.</th>
<th>Stop Code</th>
<th>Barcode</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONVALESCENT PLASMA COVID19, FFP, LD Pack 1</td>
<td>CHP1</td>
<td>a0</td>
<td>37861</td>
<td>3b</td>
<td>a0378613b</td>
</tr>
<tr>
<td>CONVALESCENT PLASMA COVID19, FFP, LD Pack 2</td>
<td>CHP2</td>
<td>a0</td>
<td>37862</td>
<td>3b</td>
<td>a0378623b</td>
</tr>
<tr>
<td>CONVALESCENT PLASMA COVID19, FFP, LD Pack 3</td>
<td>CHP3</td>
<td>a0</td>
<td>50050</td>
<td>3b</td>
<td>a0500503b</td>
</tr>
<tr>
<td>CONVALESCENT PLASMA COVID19, FFP, LD</td>
<td>CHP4</td>
<td>a0</td>
<td>37863</td>
<td>3b</td>
<td>a0378633b</td>
</tr>
</tbody>
</table>
Transfer of CP to the ward

- The Transfusion Laboratory will issue the CP as per normal procedures
- Issuing of CP will be recorded by transfusion Lab on a trial log:
  - Trial number, Unit number, Date & Time ...
- Yellow trial bags will be provided for transfer of the unit to the ward.
- Simple Administration guides will be supplied to accompany the CP
- CP to be transferred to the ward following local procedures.
Administering CP

- All standard administration transfusion safety checks must be undertaken as per hospital policy.
  - Assess patient for risk of Transfusion associated circulatory overload (TACO)
  - All bedside transfusion safety checks (component integrity & expiry, cross check tag, unit label, prescription, and positive patient identification)
  - Don’t forget adjusted dosing for paediatrics, volume to give rather than 1 unit.
  - The CP should be infused according to hospital transfusion standard practice.
    - As soon as possible and within 4 hours of defrosting if at room temperature or up to 24 hours if refrigerated between 2 – 6°C
- Date of transfusion should be documented on the eCRF and all other transfusion observations in patients medical notes as per standard hospital policy.
- Patients can receive other blood products, if and as required.
- Provided the patient has not had any serious adverse reactions, the research team will request a second unit from the transfusion laboratory.
ASSESSING PATIENTS FOR RISK OF TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD (TACO) PRIOR TO CONVALESCENT PLASMA TRANSFUSIONS

Staff should use this checklist, based on the TACO checklist included in the annual SHOT reports, to perform a formal pre-transfusion risk assessment for Transfusion- associated circulatory overload (TACO) in patients receiving convalescent plasma.

This should be undertaken, wherever possible for all patients (especially if older than 50 years or weighing less than 50kg) receiving blood transfusion, including transfusion of convalescent plasma for COVID-19.

It is important to note that TACO is the most commonly reported cause of transfusion-related mortality and major morbidity.

Wherever risks are identified, appropriate mitigating actions need to be taken promptly- this guidance should be used in conjunction with local transfusion policies. Please consult your local transfusion staff for queries and clarifications.

TACO can occur in children and neonates as well, mostly due to errors in calculation of blood component volumes. All staff involved in paediatric and neonatal transfusions must be trained and competent to do so and use weight-based dose calculations for convalescent plasma (as ml/kg and not as bags/units of plasma).
<table>
<thead>
<tr>
<th><strong>TACO risk assessment and suggested mitigating actions</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1: Assessing cardiac risk</strong></td>
</tr>
<tr>
<td>Does the patient have a diagnosis of “Heart Failure”, congestive cardiac failure (CCF), severe aortic stenosis, or moderate-severe left ventricular dysfunction?</td>
</tr>
<tr>
<td>Is the patient on a regular diuretic?</td>
</tr>
<tr>
<td>Does the patient have severe anaemia?</td>
</tr>
<tr>
<td><strong>Step 2- Assessing pulmonary risk</strong></td>
</tr>
<tr>
<td>Is the patient known to have pulmonary oedema?</td>
</tr>
<tr>
<td>Does the patient have any respiratory symptoms of undiagnosed cause?</td>
</tr>
<tr>
<td><strong>Step 3: Assessing fluid balance</strong></td>
</tr>
<tr>
<td>Is the fluid balance clinically significantly positive?</td>
</tr>
<tr>
<td>Is the patient on IV fluids (or has been in the past 24 hours)?</td>
</tr>
<tr>
<td>Is there any peripheral oedema?</td>
</tr>
<tr>
<td>Does the patient have hypoalbuminaemia?</td>
</tr>
<tr>
<td>Does the patient have significant renal impairment?</td>
</tr>
<tr>
<td>Does the patient need other blood components?</td>
</tr>
</tbody>
</table>

*If ‘yes’ to any of the above questions*
Consider the following mitigating actions

**Step 1:**
Can the transfusion of convalescent plasma be safely deferred until the issue can be investigated, treated or resolved?

**Step 2:**
Review the need for transfusion of additional components (do the benefits outweigh the risks?)

**Step 3:**
Consider slower transfusion rates. Note that once thawed, CP should be transfused as soon as possible. If delay is unavoidable, the component may be stored and should be used within 4 hours if maintained at 20–24 °C or within 24 hours if stored at 2–6 °C

- Measure the fluid balance
- Consider giving a prophylactic diuretic
- Monitor vital signs closely, including O2 saturations
- Consider body weight dosing for other additional blood components needed especially for patients with low body weights

Repeat TACO assessment prior to every transfusion episode in every patient

*Please note that these mitigating actions help reduce risk of TACO, but TACO can still occur despite these measures and all patients need to be monitored closely as per national guidelines and local policies*
Transfusion Related Serious Adverse Events and Reactions – safety reporting and trial documentation

• All transfusion-related serious adverse events / reactions are reportable to SHOT / SABRE.
• Other reportable events include wrong component transfused (includes trial patients given standard FFP instead of convalescent plasma or a non-trial patient given CP instead of FFP).
• Ward staff to inform blood bank / transfusion practitioner of any serious reaction immediately.
• Reports to SHOT / SABRE ASAP (preferably within 48 hours) by transfusion teams.
• Must include trial name and patient’s trial number (ID) on the SHOT reporting system in addition to the other details of the reaction.
• SHOT have added CP to their website
  www.shotuk.org/reporting/covid-19-convalescent-plasma-trial-reporting
Additional assessment of safety of convalescent plasma

• For at least the first 200 participants, **both controls and patients receiving CP**, the following information will be collected on the following events occurring within the first 72 hours after randomisation:

  ✓ Sudden worsening in respiratory status

  ✓ Severe allergic reaction

  ✓ Temperature >39°C, or at least 2°C temperature rise above baseline

  ✓ Sudden drop in blood pressure of 30 mmHg or more occurring and a systolic blood pressure 80 mm or less requiring urgent medical attention

  ✓ Clinical haemolysis, defined as fall in haemoglobin plus one or more of the following: rise in lactate dehydrogenase (LDH), rise in bilirubin, positive direct antiglobulin test (DAT), positive crossmatch

  ✓ Acute thrombotic event
RECOVERY-CP

NHS Blood and Transplant Clinical Trials Unit

Trial Managers:

Gillian Powter  gillian.powter@nhsbt.nhs.uk
Samaher Sweity  samaher.sweity@nhsbt.nhs.uk
Training Attendance

Training can be cascaded – please email CTU-Recovery@nhsbt.nhs.uk once new team members have reviewed the slides:
• Put RECOVERY TRAINING Completed in the Subject field please
• We also need your name, role and hospital name.

Let us know when you are ready to open for recruitment
Thank You!

Any Questions